Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05268614 · ClinicalTrials.gov registry record · Phase 2
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
A Phase 2 study of Oropharyngeal Squamous Cell Carcinoma, sponsored by University of Florida.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 3
- Study locations
NCT05268614 is a Phase 2 study of Oropharyngeal Squamous Cell Carcinoma that is actively recruiting participants, run by University of Florida. The registered enrollment target is 250 participants, above the 199-participant average among 14 other Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target (26% higher). The trial reports 3 study locations across 2 states.
The verdict
NCT05268614, a Phase 2 study of Oropharyngeal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces Local-Regional Control rates that are similar to what has been achieved with more aggressive therapy in patients with Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma (OPSCC).
Conditions Studied
Interventions
- DRUG Cisplatin
- RADIATION Radiation therapy
Study Locations (3)
Florida
- University of Florida - Gainesville
- UF Health Proton Therapy Institute - Jacksonville
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2032-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05268614
The ClinicalTrials.gov registry entry for NCT05268614 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 199-participant average among 14 other Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target (26% higher). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oropharyngeal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cisplatin is the first listed.
NCT05268614 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, South Carolina.
Frequently Asked Questions
What is clinical trial NCT05268614 about?
NCT05268614 is a clinical study titled "Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma". This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces L...
What is the current status of trial NCT05268614?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2022-05-16. Estimated completion is 2032-06.
What conditions does trial NCT05268614 study?
This clinical trial studies the following conditions: Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05268614?
The interventions under investigation include: Cisplatin (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT05268614?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05268614 being conducted?
This trial has 3 study locations across Florida, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharyngeal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
RECRUITING · Phase 2
-
Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
RECRUITING · Phase 2
-
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RECRUITING · Phase 2
-
Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
RECRUITING · Phase 2
-
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RECRUITING · Phase 2
-
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.